What is William Blair’s Estimate for BMY Q2 Earnings?

Bristol-Myers Squibb (NYSE:BMY) – Analysts at William Blair issued their Q2 2026 earnings per share (EPS) estimates for Bristol-Myers Squibb in a report issued on Friday, February 7th. William Blair analyst M. Phipps anticipates that the biopharmaceutical company will post earnings of $1.59 per share for the quarter. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $6.75 per share. William Blair also issued estimates for Bristol-Myers Squibb’s Q3 2026 earnings at $1.65 EPS.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.81% and a negative net margin of 18.53%.

Several other equities research analysts have also weighed in on the stock. Daiwa Capital Markets upgraded shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research note on Wednesday, November 13th. Jefferies Financial Group upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and increased their price target for the stock from $63.00 to $70.00 in a research report on Monday, December 16th. Sanford C. Bernstein initiated coverage on Bristol-Myers Squibb in a research report on Thursday, October 17th. They set a “market perform” rating and a $56.00 price objective for the company. Cantor Fitzgerald increased their target price on Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Finally, Truist Financial boosted their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Trading Up 0.8 %

Bristol-Myers Squibb stock opened at $55.99 on Monday. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $61.10. The firm’s 50-day moving average is $57.48 and its 200-day moving average is $53.97. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. The company has a market cap of $113.56 billion, a P/E ratio of -12.67, a PEG ratio of 2.13 and a beta of 0.45.

Bristol-Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd were given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 4.43%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date was Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio is -56.11%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BMY. Signature Estate & Investment Advisors LLC boosted its holdings in Bristol-Myers Squibb by 46.6% during the fourth quarter. Signature Estate & Investment Advisors LLC now owns 8,724 shares of the biopharmaceutical company’s stock worth $493,000 after buying an additional 2,775 shares in the last quarter. Zions Bancorporation N.A. boosted its stake in shares of Bristol-Myers Squibb by 12.2% during the 4th quarter. Zions Bancorporation N.A. now owns 188,331 shares of the biopharmaceutical company’s stock worth $10,652,000 after acquiring an additional 20,480 shares in the last quarter. GQG Partners LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter worth $2,990,000. Modern Wealth Management LLC raised its position in shares of Bristol-Myers Squibb by 36.4% during the fourth quarter. Modern Wealth Management LLC now owns 17,398 shares of the biopharmaceutical company’s stock worth $966,000 after purchasing an additional 4,647 shares during the period. Finally, CoreFirst Bank & Trust purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at $377,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.